PNC-27

PNC-27 is a synthetic 27-amino-acid peptide derived from the transactivation domain of the p53 tumor-suppressor protein, engineered to bind HDM-2 (also called MDM-2), a protein overexpressed on the membrane of many cancer cell types. In cell-culture research, PNC-27 has been studied for its ability to form pores in the membranes of HDM-2-expressing cancer cells, triggering rapid necrosis, while leaving healthy cells (which lack surface HDM-2) largely unaffected. It is investigated exclusively as a laboratory research compound and has not been evaluated in human clinical trials.

Key Benefits Studied in Research

• Investigated in vitro for its ability to selectively target and induce necrosis in HDM-2-expressing cancer cell lines
• Studied for a proposed mechanism that spares normal, non-cancerous cells lacking membrane-bound HDM-2
• Explored as a research tool for understanding p53/HDM-2 pathway biology in oncology research settings

FDA-Approved Uses

PNC-27 has no FDA approval for any human or animal use. It is not a recognized pharmaceutical, cancer treatment, or dietary supplement, and is sold exclusively as a research chemical for controlled laboratory use, not for consumption.

Where Researchers Source It

Researchers can source PNC-27 through NextGenPeps (use code GENBONUS for 10% off).

Side Effects

• No independent human safety or side-effect data exists, as PNC-27 has not progressed to clinical trials
• In vitro work suggests a cancer-cell-selective mechanism, but this does not establish a safety profile for whole-organism or human use
• Unregulated, non-clinical-grade sourcing carries general risks common to all research peptides (purity variability, contamination)

Contraindications

• Not established for human or animal use under any circumstance — treat as an uncharacterized compound with unknown safety margins
• Should not be combined with other experimental research compounds without independent risk assessment, given the lack of interaction data

Mechanism of Action

PNC-27 is modeled on the p53 transactivation domain, which normally interacts with HDM-2 as part of the cell’s own tumor-suppression signaling. Many cancer cell types overexpress HDM-2 on their outer membrane, unlike most normal cells. In preclinical studies, PNC-27 is reported to insert into the membrane of HDM-2-expressing cells and form pores, causing rapid, necrosis-like cell death, a mechanism distinct from apoptosis-inducing chemotherapeutics. Its precise binding kinetics, selectivity margins, and pharmacokinetics have not been independently published or peer-reviewed at a clinical level.

Research Background

PNC-27 originates from academic research into p53-derived peptides as a potential alternative to conventional chemotherapy’s mechanism of action. Published in vitro studies have examined its effects on various cancer cell lines, but the compound remains in early-stage, non-clinical research and has not been evaluated for safety or efficacy in living organisms at a regulatory level. Researchers citing this work should treat it as preliminary, mechanism-focused laboratory data rather than evidence of therapeutic effect.

Disclaimer: This page is for educational and research-reference purposes only. PNC-27 is not approved for human or animal use and is not a dietary supplement, drug, or cancer treatment. Nothing on this page constitutes medical advice. Consult a qualified professional before making any health-related decisions.